Narrow Band Ultraviolet (NBUVB) effect on the treatment of inflammatory acne

Comparing the therapeutic efficacy of oral azithromycin plus Narrow Band Ultraviolet B (NBUVB) with oral azithromycin alone in the treatment of moderate to sever inflammatory facial acne vulgaris

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112288550N1

Enrollment

Registered

2012-02-04

Start date

2010-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris. Acne vulgaris

Interventions

Intervention 1: Group 2: systemic azithromycin 500 mg every other day and NBUVB 1200 mj/sec two timesd weekly for one month. Intervention 2: Group 1: systemic azithromycin 500 mg every other day.

Treatment - Devices

Treatment - Drugs

Group 2: systemic azithromycin 500 mg every other day and NBUVB 1200 mj/sec two timesd weekly for one month.

Group 1: systemic azithromycin 500 mg every other day.

Eligibility

Sex/Gender

All

Age

15 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Mail and female patent with moderate to sever inflammatory vulgaris. Exclusion criteria: 1-Pregnancy and breastfeeding; 2-History of topical and systemic anti acne treatment from 1 month ego; 3-Photosensitivity.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Inflammatory acne lesions (totally and differentially). Timepoint: 1 month. Method of measurement: lesion count.	—

Secondary

Measure	Time frame
Patient's satisfaction of treatment. Timepoint: 1 month. Method of measurement: Patient idea.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Esmaeil Rafiee

Ahvaz Jundishapur University of Medical Sciences

esmail.rafiee@gmail.com , rafiee.e@ajums.ac.ir+98 61 1222 2114

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026